Become a Member

Topic Archives: Access Group

  • written by reader Did Teeka Tiwari ever give an update on these two pre-IPO investments that he recommended?

    Since I am not a subscriber to Teeka’s expensive newsletters, I wonder anyone can inform us whether he ever gave an update regarding these two pre-IPO investment recommendations: ei.ventures and Robot Cache. Is he still confident that these two pre-IPO investments can create huge returns? If so, did he mention something about when investors can […]

    Leave a comment Read More
  • “How to Play Genomics for Potential Triple-Bagger Gains”

    Looking into a teaser pick for Marc Lichtenfeld's new Firstline Investor Alert

    17 Comments Read More
  • “The Next 8,539% Biotech Breakout … Beginning April 26”

    Ah, a good old promise of biotech riches — I haven’t dug into one of these in ages, nothing beats the wild biotech stocks that can see their share price climb 200% (or fall 90%) on a single bit of news. This tease is from Marc Lichtenfeld, whose biotech stuff we’ve looked at several times […]

    27 Comments Read More
  • “The Greatest Little Stock Nobody’s Ever Heard Of” (Marc Lichtenfeld)

    Now this is a nice promise: “If This Stock Doesn’t Double Between Now and June 25, I’ll Write You an Apology – Along With a Check for $1,250” Of course, one assumes that this only applies to the folks who pony up that same $1,250 for a subscription to the Access Research Group newsletter (and, […]

    13 Comments Read More
  • “Double your money … Guaranteed” Access Group

    This is an ad that probably many of you have already seen, from Marc Lichtenfeld for his Access Group newsletter. And yes, like so many ads do, they’re guaranteeing that you’ll double your money if you invest in this idea. Which gives me a chance for a quick little digression before we dig into the […]

    9 Comments Read More
  • Access Group (defunct)

    Healthcare-focused newsletter, recommended stocks primarily of emerging device and biotech companies. Was helmed by Marc Lichtenfeld, who moved on to other publications, but stopped publishing after a short while — Lightning Trend Trader, a current publication of Lichtenfeld’s with The Oxford Club, sometimes covers biotech stocks.

    2 Reviews Read More
  • “Hunt Down Cancer Cells and Zap them Dead” Access Group

    Today’s teaser ad is from Marc Lichtenfeld and his Access Group — they specialize in part on medical and biotech stocks, and the first two ads we’ve looked at them are in that area. The first one was for the “$4 Cancer Detection Device that could go to $196,” which you might remember turned out […]

    30 Comments Read More
  • Access Group: “$4.75 Cancer Detection Device co. could got to $196”

    This one comes in from what looks to be a new newsletter service called “The Access Group” that will run you $2,750 a year. Phew. This is a service that they claim will enable individual investors to get access to the kind of research hedge fund companies used to pay these analysts $30,000 a year […]

    21 Comments Read More
  • Comments

  • Travis, As a past subscriber to Access Group I was not impressed with the performance of his picks. Lost money on bot...

  • http://finance.yahoo.com/echarts?s=MELA#symbol=MELA;range=2yI'm just killing time between church & the BbQ at th...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info